ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Adalimumab biosimilars compared to originator: impact on uveitic macular edema.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of originator or biosimilar adalimumab on uveitic macular edema (UME) in refractory non-infectious uveitis.
methodsMulticenter retrospective cohort study of non-infectious uveitis patients who received either originator or biosimilar adalimumab. Serial optical coherence tomography monitored UME over 24 months. Main outcomes were time to UME resolution in eyes with baseline UME, and time to UME onset in eyes without baseline UME.
resultsThe study included 94 patients (146 eyes): 56 patients (84 eyes) received originator adalimumab and 38 (62 eyes) biosimilars. Median follow-up was 24.0 (IQR 24.0, 24.0) and 12.0 (IQR 6.0, 24.0) months, respectively. Baseline UME was present in 27/84 originator (32.1%) and 22/62 biosimilar eyes (35.5%; p = 0.84). Among eyes with baseline UME, mean CRT decreased in both groups (originator 379.5 ± 68.3 to 304.8 ± 55.1 μm; biosimilar 440.3 ± 125.2 to 267.6 ± 162.4 μm; p < 0.0001) and remained stable in eyes without baseline UME (p = 0.78). UME resolved in 24/27 originator (88.9%) and 13/22 biosimilar eyes (59.1%; p = 0.02). Median time to resolution was 3 and 6 months, respectively; in multivariable analysis, biosimilar use (HR 0.44, 95% CI 0.25-0.77, p = 0.003) and bilateral UME (HR 0.48, 95% CI 0.31-0.76, p = 0.001) were independently associated with delayed resolution. Relapse after resolution occurred in 15/37 eyes (40.5%). New UME developed in 15/57 originator (26.3%) and 7/40 biosimilar eyes (17.5%), with no significant difference in risk (HR 0.99, 95% CI 0.37-2.64).
conclusionsTreatment with either originator or biosimilar adalimumab is associated with improvement in UME among non-infectious uveitis patients. Treatment with biosimilars resulted in delayed resolution of UME.
Indexed as
Identifiers
42684441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.